Picture of AIM ImmunoTech logo

AIM AIM ImmunoTech Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m+57.3%
3m+3.36%
6m-17.99%
1yr-19.48%
Volume Change (%)
10d/3m+134.37%
Price vs... (%)
52w High-57.23%
50d MA+29.31%
200d MA-13.89%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-50.27%
Return on Equity-39.91%
Operating Margin-16278.36%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of AIM ImmunoTech EPS forecast chart

Profile Summary

AIM ImmunoTech Inc. is an immuno-pharmaceutical company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. The Company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
December 17th, 1990
Public Since
November 6th, 1995
No. of Shareholders
150
No. of Employees
21
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
48,082,275

AIM Share Price Performance

Upcoming Events for AIM

FAQ

Or unlock with your email

Or unlock with your email